Coya Therapeutics Secures Key Financing In Its Fight Against Myriad Diseases

Dr. Howard Berman, Ph.D, CEO of Coya Therapeutics Inc COYA, were guests on Benzinga’s All Access.

Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. The company is currently developing multi-modality Treg therapies for neurodegenerative, autoimmune and metabolic diseases.

Coya has secured key financing that is funding its research and development to enhance the body’s T cells.

Watch the full interview here:

Featured photo by Hal Gatewood on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.